Overall Score

Growth Durability

Revenue base remains intact with gross profit margin at 66.1% and revenue per share of 5.25.

Operating performance is still weak, with EBIT margin at -8.5% and net margin at -13.5%.

Cash generation is limited, as operating cash flow margin is 6.9% and free cash flow per share is only 0.03.

Profitability

Returns remain deeply negative, including ROE of -8.2%, ROIC of -7.2%, and ROA of -13.9%.

Interest coverage is negative at -1.1x, indicating earnings do not cover interest expense.

High SG&A at 62.4% of revenue continues to pressure operating leverage.

Financial Strength

Liquidity is acceptable with a current ratio of 1.89 and quick ratio of 1.07.

Leverage remains elevated, with debt-to-assets at 76.4% and net debt to EBITDA at 36.1x.

Cash ratio of 0.50 provides some near-term cushion, but solvency remains weak.

Cash Flow Quality

Operating cash flow is positive at 0.24x of revenue, but conversion remains modest.

Capex consumes most operating cash flow, with capex-to-OCF at 92.6%.

Free cash flow yield is only 0.28%, reflecting very limited shareholder cash generation.

Valuation

EV/Sales of 2.41x is not demanding for a growth-oriented medtech name.

However, EV/EBITDA is extremely high at 146.0x and P/FCF is 355.8x, limiting valuation support.

Negative earnings and book value metrics make traditional value anchors unreliable.